Michael Boyer
Impact in
- Hardware and Architecture top 0.2%
- Parallel Computing and Optimization Techniques
- Pulmonary and Respiratory Medicine top 0.05%
- Lung Cancer Treatments and Mutations
- Occupational and environmental lung diseases
- Pleural and Pulmonary Diseases
Papers in
-
- Lung Cancer Treatments and Mutations 102
- Lung Cancer Diagnosis and Treatment 31
- Occupational and environmental lung diseases 19
- Oncology 144
- Lung Cancer Research Studies 49
- Cancer Immunotherapy and Biomarkers 36
- Colorectal Cancer Treatments and Studies 27
- HER2/EGFR in Cancer Research 14
- Co-authors
- Kevin Skadron (9 shared papers)Shuai Che (4 shared papers)Jeremy W. Sheaffer (3 shared papers)David Tarjan (6 shared papers)Jiayuan Meng (3 shared papers)U. Gatzemeier (3 shared papers)Stephen Clarke (34 shared papers)James T. Symanowski (5 shared papers)
- Journals
- Journal of Clinical Oncology (61 papers)Journal of Thoracic Oncology (29 papers)Annals of Oncology (25 papers)Lung Cancer (14 papers)British Journal of Cancer (9 papers)
- Partner nations
- AustraliaUnited StatesCanada
In The Last Decade
Michael Boyer
323 papers receiving 20.1k citations
Michael Boyer's Hit Papers
Peers
Comparison fields: 5 of 188
- Hardware and Architecture 2.7k
- Pulmonary and Respiratory Medicine 7.8k
- Oncology 6.4k
- Cancer Research 1.8k
- Computer Networks and Communications 2.4k
Countries citing papers authored by Michael Boyer
This map shows the geographic impact of Michael Boyer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Boyer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Boyer more than expected).
Fields of papers citing papers by Michael Boyer
This network shows the impact of papers produced by Michael Boyer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Boyer. The network helps show where Michael Boyer may publish in the future.
Co-authors
The 25 scholars most cited alongside Michael Boyer, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 333 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations Hit paper breakdown → | 2013 | 2516 |
| 2 | Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma Hit paper breakdown → | 2003 | 2377 |
| 3 | Rodinia: A benchmark suite for heterogeneous computing Hit paper breakdown → | 2009 | 2336 |
| 4 | The Multinational Association for Supportive Care in Cancer Risk Index: A Multinational Scoring System for Identifying Low-Risk Febrile Neutropenic Cancer Patients Hit paper breakdown → | 2000 | 830 |
| 5 | Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study Hit paper breakdown → | 2017 | 570 |
| 6 | A performance study of general-purpose applications on graphics processors using CUDA Hit paper breakdown → | 2008 | 494 |
| 7 | 2002 | 436 | |
| 8 | The dynamics of change: Cancer patients' preferences for information, involvement and support Hit paper breakdown → | 1997 | 435 |
| 9 | Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial Hit paper breakdown → | 2017 | 406 |
| 10 | 2010 | 273 | |
| 11 | 2000 | 241 | |
| 12 | 2015 | 240 | |
| 13 | 2012 | 220 | |
| 14 | 2010 | 216 | |
| 15 | Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1–Positive Advanced NSCLC Hit paper breakdown → | 2021 | 211 |
| 16 | 2016 | 197 | |
| 17 | 2009 | 186 | |
| 18 | 1990 | 185 | |
| 19 | 1999 | 180 | |
| 20 | 2021 | 173 |
About Michael Boyer
Michael Boyer is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Molecular Biology, Surgery and Cancer Research, having authored 333 papers that have together received 20.7k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (102 papers), Lung Cancer Research Studies (49 papers), Cancer Immunotherapy and Biomarkers (36 papers), Lung Cancer Diagnosis and Treatment (31 papers), Colorectal Cancer Treatments and Studies (27 papers), Occupational and environmental lung diseases (19 papers), Cancer therapeutics and mechanisms (17 papers) and HER2/EGFR in Cancer Research (14 papers). The work is most often cited by research in Hardware and Architecture (2.7k citations), Pulmonary and Respiratory Medicine (7.8k citations), Oncology (6.4k citations), Cancer Research (1.8k citations) and Computer Networks and Communications (2.4k citations). Michael Boyer has collaborated with scholars based in Australia, United States and Canada. Frequent co-authors include Kevin Skadron, Shuai Che, Jeremy W. Sheaffer, David Tarjan, Jiayuan Meng, U. Gatzemeier, Stephen Clarke, James T. Symanowski, Nicholas J. Vogelzang and James J. Rusthoven. Their work appears in journals such as Journal of Clinical Oncology, Journal of Thoracic Oncology, Annals of Oncology, Lung Cancer and British Journal of Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.